Takeda Pharmaceutical's Asset Writedowns and Impairment rose 24934.76% to $49.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 20687.41%. This contributed to the annual value of $699.3 million for FY2025, which is 3277.04% down from last year.
According to the latest figures from Q4 2025, Takeda Pharmaceutical's Asset Writedowns and Impairment is $49.7 million, which was up 24934.76% from $575.4 million recorded in Q3 2025.
In the past 5 years, Takeda Pharmaceutical's Asset Writedowns and Impairment registered a high of $823.1 million during Q3 2023, and its lowest value of $484156.0 during Q2 2021.
In the last 5 years, Takeda Pharmaceutical's Asset Writedowns and Impairment had a median value of $108.1 million in 2022 and averaged $173.6 million.
Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first crashed by 9930.18% in 2021, then soared by 2263930.36% in 2022.
Takeda Pharmaceutical's Asset Writedowns and Impairment (Quarter) stood at $115.9 million in 2021, then crashed by 63.25% to $42.6 million in 2022, then grew by 20.33% to $51.3 million in 2023, then crashed by 72.26% to $14.2 million in 2024, then skyrocketed by 249.35% to $49.7 million in 2025.
Its Asset Writedowns and Impairment was $49.7 million in Q4 2025, compared to $575.4 million in Q3 2025 and $16.3 million in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value